We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Risk Factor Identified for Life-Threatening Disease in Premature Infants

By LabMedica International staff writers
Posted on 03 Feb 2014
Many premature infants suffer a life-threatening bowel infection called necrotizing enterocolitis (NEC), and a marker has been identified in those infants who are at risk for the infection.

Since thrombocytopenia and bowel ischemia are consistent findings in advanced NEC, two potential biomarkers, reticulated platelets (RP) and intestinal alkaline phosphatase (iAP), were investigated. More...


Scientists at Loyola University Medical Center (Maywood, IL, USA) prospectively enrolled 177 infants born at less than 32 weeks' gestation and who were less than 1,500 grams in weight, from 2009 to 2012. Blood samples were collected from these infants within 72 hours of birth and weekly for four weeks to measure reticulated platelets (RP) and intestinal alkaline phosphatase (iAP). The percentage of reticulated platelets was determined by flow cytometry and serum iAP levels were determined by gel electrophoresis.

Of the 177 infants, 15 (8.5%) developed NEC and of these, 93% had low RP levels and 60% had high iAP. Those infants with low RP levels were significantly more likely to develop NEC while those with high iAP showed a similar trend. The study found that infants who would go on to develop NEC had significantly higher iAP levels at week four. While classically NEC occurs at week three of life, feeds of infants in the neonatal intensive care unit are advanced slowly and typically not started until near the end of the first week. The later initiation of feeds in the preterm infants in the study might be a reflection of them being extremely low birthweight infants (birthweight less than 1,000 g) and unstable at birth, delaying the onset of enteral feeds.

The authors concluded that as NEC affects up to 10% of very low birthweight infants, an already vulnerable population, it is important to discover reliable tests to detect those infants in this subpopulation who are most at risk of developing NEC in order to work towards prevention. Currently, no one test exists that can predict NEC; however, the team’s study suggests that the findings of low reticulated platelets and a high iAP may be useful in identifying those preterm infants at risk of NEC. Jonathan Muraskas, MD, the senior author, said, “Decreased reticulated platelets serve as a sensitive indicator for NEC onset. Further research also may find that infants with elevated iAP levels may be at risk.” The study was published online in the November 2013 issue of the Journal of Pediatric Surgery.

Related Links:

Loyola University Medical Center



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AI-powered ctDNA analysis provides clinicians with a new lens to monitor disease evolution (Photo courtesy of Brandon Stelter, Katie Han, Kyle Smith, and Paul Northcott)

AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy

Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.